Preventive effect of ramelteon on delirium in IC

umaguchi Atushi0 个研究点目标入组 220 人开始时间: 2021年3月11日最近更新: 2023年10月17日

适应症

试验速览

暂无简介。

•1) ICU patients 18 years old or more, expected to stay in ICU for over 48 hours.
•2) Patients registered within 48hours of ICU admission and administrated first medication on the registration day.

•1) Patients under 18 years old.
•2) Allergy to ramelteon.
•3) Patients with severe liver injury (T-Bil >= 10 mg/dL, or ALT >= 750 IU/L).
•4) Patients receiving fluvoxamine maleate.
•5) Patients already receiving ramelteon therapy before admission.
•6) Patients expected to leave ICU within 48 hours of admission.
•7) Patients expected to die within 48 hours of admission or be excluded from active treatment.
•8) Pregnant or lactating women.
•9) Patients expected to be difficult to evaluate delirium by CAM-ICU due to neurological problems such as post-cardiac arreest, head trauma, stroke, or other illness.
•10) Absence of written informed consent.

发起方

umaguchi Atushi